***TITLE: Form FDA 1572 Management***

***SOP #*** RM XX.XX

***Author(s):***

 ***Approved by Date***

***\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_***

 ***\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_***

***Approval:***

 ***Approved by Date***

***\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_***

 ***\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_***

***Renewed Effective date Description***

 ***Approved by***

 ***\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_***

 ***\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_***

***\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_***

|  |
| --- |
| **Instructions for modifying this template:**1. This is a template and should be used as such. Please use this in the manner most appropriate for your research unit.
2. Text in blue is language you may want to modify as most applicable for your area. However, anything in this template can and may be modified as appropriate for your area while accounting for your interpretation of the most current FDA Guidance.
3. After you have modified this SOP template, do not forget to remove the “Instructions for modifying this template” table.
 |

**I. SCOPE/PURPOSE**

The purpose for this SOP is to describe the management for Form FDA 1572 completion.

**II. ALLOWABLE EXCEPTIONS**

This SOP is to be followed without deviation.

**III. RELEVANT REGULATIONS/GCPS**

FDA (Food and Drug Administration) Requirements

**IV. DEFINITIONS/ACRONYMS**

CAP—College of American Pathologists

 CLIA—Clinical Laboratory Improvement Amendments

 Statement of Investigator—Form FDA 1572

**V. RESPONSIBLE PERSONNEL**

This SOP applies to the following – Study Investigators, Study Coordinators, Regulatory

Affairs and sponsors.

**VI. DETAILS**

 **I. Form FDA 1572**

a. The Principal Investigator (PI) will sign and date the Form FDA 1572, which will represent an agreement to conduct the study in accordance with all federal regulation as well as Good Clinical Practices (GCP).

b. The original document will be provided to the Sponsor when applicable.

c. A copy will be presented to the Institutional Review Board (IRB) for their study files with the initial submission.

d. A copy will be retained on site and filed with the study regulatory documents.

 **II. Specific elements of the Form FDA 1572**

a. Box 1: The PI’s formal name, the Institution name, and the administrative address for the Investigator will be listed.

i. The formal name of the Investigator will match the name listed on the physician medical license.

ii. The Institution will appear as University of Alabama at Birmingham.

iii. The administrative address will include the building code and office number of the Principal Investigator.

b. Box 2: A copy of the signed and dated CV will be provided to the Sponsor as a statement of PI qualifications.

i. The CV will be updated every 2 years.

ii. At the Sponsor’s request an abbreviated CV may be completed and filed in place of the full CV.

c. Box 3: The study site addresses listed are the physical location that research subjects may be seen for study visits.

i. All addresses where study supplies will be shipped including the research pharmacy (as applicable) should also appear in Box 3.

ii. Key administrative offices (as applicable), including where regulatory binders are kept, should also appear in Box 3.

d. Box 4: In addition to the central laboratories that will be used by the Sponsor, the University of Alabama at Birmingham (UAB) Hospital Laboratory will be listed on all Forms FDA 1572 as a local laboratory.

i. The UAB Hospital Laboratory name and address will be listed as it appears on the laboratory CAP and CLIA certificates.

e. Box 5: The Institutional Review Board of record will be listed here.

f. Box 6: Study Sub-Investigators will be listed and for the purpose of Industry sponsored studies, this will include medical doctors and nurse practitioners.

g. Box 7: The name and protocol number will be listed here.

h. Box 8: The study sponsor will indicate the study phase to be marked.

i. The PI will sign and date the document at the same time.

 i. Electronic signatures are acceptable per the FDA Guidance.

 **III. Updating of the Form FDA 1572**

a. The Form FDA 1572 will be updated immediately if there are any pertinent study related changes to the current document on file.

i. Removal of sub-investigators will not require an updated Form FDA 1572.

ii. There are two instances when it is necessary for an investigator to complete and sign a new Form FDA 1572: when an investigator is participating in a new protocol that has been added to the IND and when a new investigator is added to the protocol (21 CFR 312.53(c)).

iii. If there are other changes to information contained on a signed and dated Form FDA 1572 (e.g., an IRB address change, the addition of new sub investigators, the addition of a clinical research lab), the investigator should document the changes in the clinical study records and inform the sponsor of these changes, so that the sponsor can appropriately update the IND. The Form FDA1572 itself does not need to be revised and a new Form FDA1572 need not be completed and signed by the investigator. The sponsor can accumulate certain changes and submit this information to the IND in, for example, an information amendment or a protocol amendment.

b. The original or a copy of the document will be provided to the Sponsor in a timely manner per the sponsor’s guidelines.

c. A copy of the updated form will be forwarded to the study’s IRB with a summary of changes.

d. A copy of the form will be filed on site with the regulatory documents for the study.

e. The outdated forms will remain filed with the study documents.

**VII. QA**

The 1572 should be reviewed for accuracy when the IRB renewal/annual progress report occurs. It is not necessary to change the 1572 annually, but at this time will provide a reminder if in fact a location or if clinical personnel listed on the 1572 have changed.

**VIII. APPENDICES/RESOURCES**

Form FDA 1572: <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM074728.pdf>

 Form FDA 1572 Guidance: <http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM214282.pdf>

**IX. RELATED SOPS**

**NA**